BioSpace News Archive

This new kit employs a novel enzymatic fragmentation system that combines fragmentation, end repair and dA-tailing in a single tube, and utilizes a single protocol regardless of input amount or GC content.

The company has also developed sophisticated data systems for tracking such large numbers of human genetic samples, for efficiently processing and managing the flow of many petabytes of genetic data, and for maintaining auditable quality at large scale.

The name Sotera was inspired by the Greek goddess of safety, Soteria, and reflects the Company’s unwavering commitment to global health.

The presentation will include a full data analysis, beyond the top-line results previously reported by the company in July and October 2017.

As described in the offering circular published by Orphazyme A/S on 6 November 2017, the Company applied to the FDA for the designation in September 2017.

WIB launched Boardroom Ready in 2016.

The poster’s authors include scientists from the laboratories of Professor John Williams of the Beckman Research Institute at the City of Hope and Professor Ulrich Rodeck at Thomas Jefferson University, along with Dr. Margaret Karow, Senior Vice President of Drug Discovery and Preclinical Development at Akriveia Therapeutics.

The Imaging Phenomics Company is pleased to announce that James Golando, Chief of Operations at Median Technologies will present on “Optimizing Imaging in Oncology Clinical Trials” during the upcoming Medidata NEXT Global 2017.

These results are included in the Company’s Quarterly Report on Form 10-Q, which has been filed with the U.S. SEC and is available at www.sec.gov.

ATLAS continues to demonstrate superiority to in silico methods of neoantigen identification in multiple tumor types.